Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5786548 | 0.95 | SCN9A (0.41) | SCN9AHRH4L3MBTL1CHEK2KDM4E | |
| SCHEMBL6329605 | 0.95 | SCN9A (0.47) | SCN9AHRH4L3MBTL1CHEK2KDM4E | |
| SCHEMBL5806584 | 0.93 | SCN9A (0.41) | SCN9AHRH4L3MBTL1CHEK2KDM4E | |
| SCHEMBL5786619 | 0.89 | ADORA2A (0.47) | SCN9AHRH4L3MBTL1CHEK2KDM4E | |
| SCHEMBL5786617 | 0.89 | ADORA2A (0.47) | SCN9AHRH4L3MBTL1CHEK2KDM4E | |
| Hydrochloric Acid SCHEMBL5785987 | 0.88 | ADORA2A (0.46) | SCN9AHRH4L3MBTL1CHEK2KDM4E | |
| Hydrochloric Acid SCHEMBL6331043 | 0.88 | ADORA2A (0.46) | SCN9AHRH4L3MBTL1CHEK2KDM4E | |
| SCHEMBL5786540 | 0.88 | BPTF (0.40) | SCN9AHRH4CHEK2CYP2D6CHRM1 | |
| SCHEMBL5806581 | 0.86 | BPTF (0.39) | SCN9AHRH4L3MBTL1CHEK2KDM4E | |
| SCHEMBL5823230 | 0.84 | HRH4 (0.44) | SCN9AHRH4L3MBTL1CHEK2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | claimed |
| EP-1685115-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005042501-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | SCN9A 801/4885HRH4 145/4885L3MBTL1 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.